RxDoctor Payments Data

Shazia Siddiqui, MD

Pain Medicine · Lafayette, INNPI 1629001680

Payments from drug & device makers

What this record shows

14 manufacturers reported payments, led by Relievant Medsystems, Inc. at 38.2% of the total. Reporting peaked in 2023 at $2,212 and has fallen 89.0% since, to $244 in 2025.

$4,646in general payments, 2019–2025

Across 98 payments — averaging $47.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Relievant Medsystems, Inc.$2K
  • Boston Scientific$2K
  • Vertos Medical, Inc.$713
  • Medtronic$217
  • Painteq LLC$194
  • Tersera Therapeutics LLC$45
  • plus $189 from 8 others

What the payments were for

  • Travel & lodging$2,30650%
  • Food & beverage$2,34050%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,646 in reported general payments places this provider in the 60th percentile of 128 pain medicine providers in Indiana.

See all pain medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$285,411
Medicare patients
495
Services billed
2,437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,940$42,257
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen528$14,849
BelbucaBuprenorphine Hcl18$8,551
Naloxone Hcl128$5,830
Gabapentin289$5,195
Pregabalin113$4,136
Oxycodone Hcl147$2,772
Morphine Sulfate52$1,555
Tramadol Hcl224$1,530
Baclofen79$1,094
Tizanidine Hcl73$1,030
Cyclobenzaprine Hcl56$823
Acetaminophen-CodeineAcetaminophen With Codeine52$433
Hydromorphone Hcl31$405
Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen29$336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$34$8,55118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 128 pain medicine providers in Indiana.

Other pain medicine in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →